São Paulo - Delayed Quote • BRL Dr. Reddy's Laboratories Limited (R1DY34.SA) Follow Compare 13.63 0.00 (0.00%) At close: January 27 at 1:23:42 PM GMT-3 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for R1DY34.SA 1D 5D -7.28% 1M -13.46% 3M -5.02% 6M -16.54% YTD -16.07% 1Y 19.94% 5Y 5.97% All 5.97% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: R1DY34.SA View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down Dr Reddy's Laboratories Ltd (RDY) Q3 2025 Earnings Call Highlights: Record Revenue Growth ... Indian drugmaker Dr Reddy's shares slide after Q3 profit miss Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business Dr. Reddy’s Q3 & 9MFY25 Financial Results Indian drugmaker Dr Reddy's says it is 'optimistic' about Trump administration Dr. Reddy’s Laboratories Allocates Equity Shares to Employees Dr. Reddy’s Boosts Workforce with Equity Allotment Dr. Reddy’s Launches Innovative Cancer Drug in India Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market